The Chief Scientific Officer of Scholar Rock Holding Corp has made multiple filings regarding disposals in January 2026, but ...
A phase 3 trial of Scholar Rock’s spinal muscular atrophy (SMA) candidate has hit its primary endpoint, sparking a 200%-plus premarket surge in the biotech’s stock price. Investors went wild despite ...
The Leading Scholar program awards various levels of scholarships recognizing the leadership skills and academic success of applicants. While a select number of applicants will be invited to campus ...
Scholar Rock contends its experimental drug for spinal muscular atrophy can achieve what none of the currently available therapies can do to treat this rare disease. After positive data from a pivotal ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound maintain muscle mass, offering another avenue to reach a key goal for the ...
The Kellogg Executive Scholar Certificate gives you the opportunity to earn a credential from a world-class business school, create a personalized leadership development path aligned with your unique ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results